R. Djukanovic (Southampton, United Kingdom), A. Papi (Ferrara, Italy)
Impact of nighttime and early morning symptoms on HRQoL and work productivity of COPD patients
S. Sullivan, J. Stephenson, Q. Cai, H. Tan, A. Kavati, M. Mocarski, J. Doshi (Seattle, Wilmington, Jersey City, Philadelphia, United States Of America)
|   |
48-week administration of olodaterol QD via Respimat® vs placebo and formoterol BID in patients with COPD: Pooled safety analysis
L. McGarvey, A. Koch, P. Sachs, A. Hamilton, K. Tetzlaff, L. Korducki, G. Ferguson (Belfast, United Kingdom; Bochum, Biberach, Germany; Stamford, Ridgefield, Livonia, United States Of America; Burlington, Canada)
| |
QVA149 provides superior peak lung function in patients with COPD
N. Barnes, S. Hashimoto, T. Nagase, H. Chen, N. Gallagher, P. D'Andrea, V. Alagappan, D. Banerji (London, Horsham, United Kingdom; Tokyo, Japan; East Hanover, United States Of America)
| |
Once-daily QVA149 demonstrates superior improvements in patient-reported dyspnea compared to tiotropium in patients with moderate-to-severe COPD: The BLAZE study
D. A. Mahler, M. Decramer, A. D'Urzo, H. Worth, T. White, V. Alagappan, H. Chen, K. Kulich, N. Gallagher, D. Banerji (Hanover, East Hanover, United States Of America; Leuven, Belgium; Toronto, Canada; Fürth, Germany; Basel, Switzerland; Horsham, United Kingdom)
| |
Once-daily QVA149 demonstrates superior outcomes in COPD patients previously treated with fixed-dose long-acting beta2-agonist/inhaled corticosteroid (LABA/ICS): The ILLUMINATE study
K. Mezzi, D. McBryan, J. Pallante, V. Alagappan, H. Chen, D. Banerji (Basel, Switzerland; East Hanover, United States Of America)
| |
Once-daily QVA149 improves symptom scores in patients with COPD
T. Welte, R. Dahl, H. Chen, N. Gallagher, P. D'Andrea, V. Alagappan, D. Banerji (Hannover, Germany; Aarhus, Denmark; East Hanover, United States Of America; Horsham, United Kingdom)
| |
QVA149 does not increase the risk of cardio- and cerebro-vascular events, pneumonia and exacerbation events compared with placebo: A network meta-analysis across multiple safety databases
H. Chen, P. D'Andrea, D. Banerji (East Hanover, United States Of America)
| |
QVA149 improves lung function and reduces exacerbations compared to tiotropium in patients with severe-to-very severe COPD: The SPARK study
J. H. Ficker, J. A. Wedzicha, M. Decramer, A. FowlerTaylor, P. D'Andrea, C. Arrasate, H. Chen, D. Banerji (Nuernberg, Germany; London, United Kingdom; Leuven, Belgium; East Hanover, United States Of America)
| |
Efficacy and safety of umeclidinium/vilanterol compared with umeclidinium or tiotropium in COPD
M. Decramer, A. Anzueto, E. Kerwin, N. Richard, G. Crater, M. Tabberer, S. Harris, A. Church (Leuven, Belgium; Houston, Medford, Research Triangle Park, United States Of America; Uxbridge, United Kingdom)
| |
Effect of moderate hepatic impairment (MHI) on umeclidinium (UMEC) and vilanterol (VI) pharmacokinetics (PK)
R. Mehta, K. Hardes, D. Kelleher, A. Preece, L. Tombs, N. Brealey (Research Triangle Park, United States Of America; Stockley Park, Slough, United Kingdom)
| |
Clinical and inhaled drug profile of COPD patients with indication for beta-blockers who are on beta-blockers
R. Malo de Molina, A. Fuster, P. J. Marcos, E. Marquez, C. Calero, G. Tirado, B. Alcazar, M. Calle, L. Puente (Madrid, Palma de Mallorca, La Coruña, Sevilla, Puerto Real, Loja, Spain)
| |
Meta analysis of asthma exacerbation rates in adult and pediatric asthmatics managed using fractional exhaled nitric oxide versus standard clinical parameters alone
J. Donohue, N. Jain, N. Herje, P. Dorinsky (Chapel Hill, Gilbert, Morrisville, United States Of America)
| |
Dedicated severe asthma services improve healthcare utilisation and quality of life
D. Gibeon, S. Regan, C. Brightling, R. Niven, A. Mansur, R. Chaudhuri, C. Bucknall, N. Thomson, K. F. Chung, L. Heaney, A. Menzies-Gow (London, Glasgow, Leicester, Belfast, Manchester, Birmingham, United Kingdom)
| |
Effects of low- vs high-dose fluticasone/formoterol combination therapy on AMP challenge in asthmatic patients
F. Kanniess, Z. Diamant, M. Lomax, M. Jain (Reinfeld, Germany; Lund, Sweden; Cambridge, United Kingdom)
| |
Safety and tolerability of acute dosing of beta-blockers in asthma
P. Short, W. Anderson, P. Williamson, B. Lipworth (Dundee, United Kingdom)
| |
Chronic dosing effects of propranolol in asthma
P. Short, W. Anderson, P. Williamson, B. Lipworth (Dundee, United Kingdom)
| |
B2-adrenoceptor genotype16 influences airway calibre but not hyperresponsiveness in asthmatics using regular B2-agonist in addition to inhaled corticosteroids
W. Anderson, P. Short, P. Williamson, A. Morrison, C. Palmer, R. Tavendale, B. Lipworth (Dundee, United Kingdom)
| |
Efficacy of carbamazepine in treatment of bronchial asthma
M. Badawy, M. Abbass (Luxor, Egypt)
| |